Skip to Content

Seagen Inc Ordinary Shares - Stock Quote SGEN

Rating as of

Morningstar's Seagen Inc Ordinary Shares Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Seagen CEO Siegall Resigns Amid Domestic Violence Allegations; Outlook Unchanged

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

We think Seagen is well positioned with its robust portfolio of internally developed antibody-drug conjugates, and we expect label expansions for its three approved drugs will push the firm into profitability in the next couple of years.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - SGEN

Seagen Inc Ordinary Shares's Company Profile

Business Description

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

21823 - 30th Drive South East, Building 3
Bothell, WA, 98021
T +1 425 527-4000
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Speculative Growth
Employees 2,675

Seagen Inc Ordinary Shares's Related News